Neoadjuvant Chemotherapy Therapy Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials
• Forums

Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer
Condition:   Sintilimab and Anlotinib in Combination With Chemotherapy Intervention:   Drug: Sintilimab and anlotinib in combination with chemotherapy Sponsor:   Tang-Du Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck
Condition:   Head and Neck Squamous Cell Carcinoma Interventions:   Drug: Nab paclitaxel;   Drug: Carboplatin;   Drug: adelbelimumab Sponsor:   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer
Condition:   Sintilimab and Anlotinib in Combination With Chemotherapy Intervention:   Drug: Sintilimab and anlotinib in combination with chemotherapy Sponsor:   Tang-Du Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck
Condition:   Head and Neck Squamous Cell Carcinoma Interventions:   Drug: Nab paclitaxel;   Drug: Carboplatin;   Drug: adelbelimumab Sponsor:   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer
Condition:   Sintilimab and Anlotinib in Combination With Chemotherapy Intervention:   Drug: Sintilimab and anlotinib in combination with chemotherapy Sponsor:   Tang-Du Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck
Condition:   Head and Neck Squamous Cell Carcinoma Interventions:   Drug: Nab paclitaxel;   Drug: Carboplatin;   Drug: adelbelimumab Sponsor:   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer
Condition:   Sintilimab and Anlotinib in Combination With Chemotherapy Intervention:   Drug: Sintilimab and anlotinib in combination with chemotherapy Sponsor:   Tang-Du Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck
Condition:   Head and Neck Squamous Cell Carcinoma Interventions:   Drug: Nab paclitaxel;   Drug: Carboplatin;   Drug: adelbelimumab Sponsor:   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer
Condition:   Sintilimab and Anlotinib in Combination With Chemotherapy Intervention:   Drug: Sintilimab and anlotinib in combination with chemotherapy Sponsor:   Tang-Du Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck
Condition:   Head and Neck Squamous Cell Carcinoma Interventions:   Drug: Nab paclitaxel;   Drug: Carboplatin;   Drug: adelbelimumab Sponsor:   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer
Condition:   Sintilimab and Anlotinib in Combination With Chemotherapy Intervention:   Drug: Sintilimab and anlotinib in combination with chemotherapy Sponsor:   Tang-Du Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck
Condition:   Head and Neck Squamous Cell Carcinoma Interventions:   Drug: Nab paclitaxel;   Drug: Carboplatin;   Drug: adelbelimumab Sponsor:   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer
Condition:   Sintilimab and Anlotinib in Combination With Chemotherapy Intervention:   Drug: Sintilimab and anlotinib in combination with chemotherapy Sponsor:   Tang-Du Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck
Condition:   Head and Neck Squamous Cell Carcinoma Interventions:   Drug: Nab paclitaxel;   Drug: Carboplatin;   Drug: adelbelimumab Sponsor:   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials

Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer
Condition:   Sintilimab and Anlotinib in Combination With Chemotherapy Intervention:   Drug: Sintilimab and anlotinib in combination with chemotherapy Sponsor:   Tang-Du Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials